Principal Investigator

Ana Abrantes

Status

Ongoing

The completed, pilot phase of this study produced a 12-week Wisepill device+SMS (text) intervention for individuals in intensive outpatient alcohol treatment who are prescribed disulfiram. The Wisepill device is a medication monitoring system equipped with technology that allows text messages to be delivered to the user. The current RCT is enrolling 75 participants with alcohol use disorder who recently initiated disulfiram. Participants are randomized into one of the following conditions: (1.) Wisepill+SMS intervention, (2.) Wisepill only (i.e.no SMS messaging), or (3.) Disulfiram only (i.e. no Wisepill). Follow-up assessments will occur at the 1-, 2-, 3- (end of intervention), and 6-month time points. Researchers will assess alcohol use, medication adherence, coping, self-efficacy, and perceived social support.

Principal Investigators

Ana Abrantes & Michael Stein

Status

Ongoing

This study aims to determine whether Transcranial Direct Current Stimulation to the DLPFC (DLPFC tDCS) + Cognitive Control Network (CCN) priming reduces craving and alters expected neural systems among 60 participants with opioid use disorder initiating buprenorphine or methadone. Participants are randomized to five 20-minute active or sham tDCS sessions. Participants will be assessed using EEG procedures and participate in Baseline and Week 2 follow-up assessments.

Principal Investigators

Michael Stein & Lisa Uebelacker

Status

Ongoing

Website

Yoga MAT

We are looking at ways to optimize a yoga intervention for people who are taking methadone or buprenorphine for opioid use disorder, and who have chronic pain. Participants are invited to attend a weekly remote yoga class, and are randomly assigned, using a factorial design, to some combination of additional components, including daily text messages, 1:1 meetings with a yoga teachers, study-specific yoga videos, and payment for class attendance. The purpose of this study is to determine which components increase engagement in yoga practice and in weekly personal yoga practice.

Principal Investigators

Ana Abrantes & Michael Stein

Status

Ongoing

This 4-year RCT will enroll 240 opioids users in methadone maintenance treatment who smoke cigarettes and are interested in nicotine replacement therapy. Participants will be assigned to either 6-weeks of electronic cigarette (JUUL) use or 6-weeks of nicotine lozenge use. Researchers will assess various smoking and health-related outcomes such as nicotine intake, tobacco toxicant exposure, lung functioning via spirometry, and respiratory symptoms over the course of 6 weeks. Participants in the electronic cigarette (JUUL) condition will be contacted 4-weeks post-intervention to discuss use of any combustible cigarettes, e-cigarettes, or other nicotine products.

Principal Investigators

Ana Abrantes & Michael Stein

Status

Completed

This 26-week observational study will examine the daily associations between opioid craving/use, negative affect, and highly palatable food (HPF) craving/consumption. We will enroll 80 individuals with opioid use disorder who are in early methadone maintenance treatment (MMT). Three, 21-day bouts of ecological momentary assessment (EMA) will help researchers understand the impact of HPF consumption on MMT outcomes. Participants will also be given a Fitbit tracker to wear during the study as a measure of physical activity engagement.

Principal Investigator

Ana Abrantes

Status

Ongoing

Building off the pilot-tested intervention, this study will test a refined version of the 6-week Personalized Feedback Intevention+Ecological Momentary Assessment (PFIcope+EMI) intervention as compared to Personalized Normative Feedback only (PNF) for Emerging Adults (EA) in a partial hospitalization program who drink alcohol to cope and binge drink. We will assess participants’ alcohol outcomes and psychiatric symptomatology at 6-weeks, 12-weeks, and 6-months to determine outcomes and feasibility/acceptability. Further, will explore mechanisms that may underlie the efficacy of the intervention for the PFIcope+EMI group utilizing the daily EMA data. We anticipate that this project will lead to the development of a well-specified, personalized, novel, technology-supported, just-in-time intervention for EA with negative effect who use alcohol to cope that can be tested in a larger multi-site trial.